Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription 25.03.2019 1 Am J Respir Crit Care Med 1 Ann Oncol 1 Ann Surg Oncol 1 Ann Thorac Surg 4 Anticancer Res 2 BMC Cancer 1 BMJ 1 Br J Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Carcinogenesis 7 Clin Lung Cancer 1 Int J Cancer 3 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Clin Oncol 1 Lancet Respir Med 22 Lung Cancer 1 Lung Cancer (Auckl) 1 Mol Carcinog 3 Oncol Rep 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Respir Crit Care Med

1. KADARA H, Sivakumar S, Jakubek Y, San Lucas FA, et al
   Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer.
   Am J Respir Crit Care Med. 2019 Mar 21. doi: 10.1164/rccm.201806-1178.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

2. HANNIGAN B, Ye W, Mehrotra M, Lam V, et al
   Liquid Biopsy Assay for Lung Carcinoma Using Centrifuged Supernatants from Fine Needle Aspiration Specimens.
   Ann Oncol. 2019 Mar 18. pii: 5384494. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Ann Surg Oncol

3. ZENG Y, Mayne N, Yang CJ, D'Amico TA, et al
   A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer.
   Ann Surg Oncol. 2019 Mar 21. pii: 10.1245/s10434-019-07318.
   PubMed     Text format     Abstract available
   
   

   
   Ann Thorac Surg

4. XIE F, Zheng X, Mao X, Zhao R, et al
   Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.
   Ann Thorac Surg. 2019 Mar 15. pii: S0003-4975(19)30347.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

5. SUKARI A, Nagasaka M, Alhasan R, Patel D, et al
   Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
   Anticancer Res. 2019;39:781-790.
   PubMed     Text format     Abstract available
   
   
6. NAKAYAMA K, Seike M, Noro R, Takeuchi S, et al
   Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.
   Anticancer Res. 2019;39:627-633.
   PubMed     Text format     Abstract available
   
   
7. SALO SAS, Ilonen I, Laaksonen S, Myllarniemi M, et al
   Malignant Peritoneal Mesothelioma: Treatment Options and Survival.
   Anticancer Res. 2019;39:839-845.
   PubMed     Text format     Abstract available
   
   
8. MIYAKE H, Matsushita Y, Watanabe H, Tamura K, et al
   Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.
   Anticancer Res. 2019;39:1067-1072.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

9. SHIBUTANI M, Maeda K, Nagahara H, Fukuoka T, et al
   The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study.
   BMC Cancer. 2019;19:241.
   PubMed     Text format     Abstract available
   
   
10. SONE K, Oguri T, Uemura T, Takeuchi A, et al
    Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
    BMC Cancer. 2019;19:246.
    PubMed     Text format     Abstract available
    
    

    
    BMJ

11. SHEN X, Zhao B
    Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.
    BMJ. 2018;362:k3529.
    PubMed     Text format     Abstract available
    
    

    
    Br J Cancer

12. CREELAN BC, Gray JE, Tanvetyanon T, Chiappori AA, et al
    Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.
    Br J Cancer. 2019 Mar 18. pii: 10.1038/s41416-019-0428.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

13. JONES CC, Bradford Y, Amos CI, Blot WJ, et al
    Cross-cancer pleiotropic associations with lung cancer risk in African Americans.
    Cancer Epidemiol Biomarkers Prev. 2019 Mar 20. pii: 1055-9965.EPI-18-0935.
    PubMed     Text format     Abstract available
    
    

    
    Carcinogenesis

14. DRAGANI TA, Colombo F, Pavlisko EN, Roggli VL, et al
    Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure.
    Carcinogenesis. 2018;39:1151-1156.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

15. WINTHER-LARSEN A, Fynboe Ebert EB, Meldgaard P, Sorensen BS, et al
    EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib.
    Clin Lung Cancer. 2019 Feb 26. pii: S1525-7304(19)30061.
    PubMed     Text format     Abstract available
    
    
16. CLAVE S, Rodon N, Pijuan L, Diaz O, et al
    Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
    Clin Lung Cancer. 2019 Feb 26. pii: S1525-7304(19)30058.
    PubMed     Text format     Abstract available
    
    
17. CODONY-SERVAT J, Codony-Servat C, Cardona AF, Gimenez-Capitan A, et al
    Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2019 Feb 21. pii: S1525-7304(19)30024.
    PubMed     Text format     Abstract available
    
    
18. OH IJ, Hur JY, Park CK, Kim YC, et al
    Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
    Clin Lung Cancer. 2018;19:e775-e781.
    PubMed     Text format     Abstract available
    
    
19. DELANEY FT, Fong KM, Lee JC
    Incidental Pulmonary Malignancies on CTAC in MPS.
    Clin Lung Cancer. 2018;19:e801-e802.
    PubMed     Text format    
    
    
20. TAMURA T, Ojima E, Satoh H
    Lung Cancers Detected on Computed Tomography Attenuation Correction Images During Myocardial Perfusion Scintigraphy.
    Clin Lung Cancer. 2018;19:e709.
    PubMed     Text format    
    
    
21. RAMAN S, Yau V, Pineda S, Le LW, et al
    Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience.
    Clin Lung Cancer. 2018;19:e803-e810.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

22. WU Y, Lin L, Shen Y, Wu H, et al
    Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
    Int J Cancer. 2018;143:3038-3040.
    PubMed     Text format    
    
    

    
    Int J Radiat Oncol Biol Phys

23. RUSTHOVEN CG
    Small Cell Lung Cancer: PCI Uncertainty and Emerging Radiosurgery Interest.
    Int J Radiat Oncol Biol Phys. 2019;103:1034-1035.
    PubMed     Text format    
    
    
24. SHINDE A, Amini A
    Challenging Current Conventions: Up-Front Stereotactic Radiosurgery Alone for Limited Brain Metastases in Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2019;103:1031-1032.
    PubMed     Text format    
    
    
25. SIVA S, Ball DL
    Single Fraction SBRT for Early Stage Lung Cancer-Less is More?
    Int J Radiat Oncol Biol Phys. 2019;103:1085-1087.
    PubMed     Text format    
    
    

    
    J Cancer Res Clin Oncol

26. CHANG H, Lee SJ, Lim J, Lee JS, et al
    Prognostic significance of metabolic parameters measured by (18)F-FDG PET/CT in limited-stage small-cell lung carcinoma.
    J Cancer Res Clin Oncol. 2019 Mar 21. pii: 10.1007/s00432-019-02848.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

27. SHAW AT, Solomon BJ, Besse B, Bauer TM, et al
    ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Mar 20:JCO1802236. doi: 10.1200/JCO.18.02236.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Respir Med

28. JASSEM J
    Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.
    Lancet Respir Med. 2018;6:808-810.
    PubMed     Text format    
    
    

    
    Lung Cancer

29. HU SY, Hsieh MS, Hsu HH, Tsai TM, et al
    Corrigendum to "Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas" [Lung Cancer 126 (2018) 189-193].
    Lung Cancer. 2019 Mar 13. pii: S0169-5002(19)30349.
    PubMed     Text format    
    
    
30. BRAVACCINI S
    What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
    Lung Cancer. 2019 Mar 11. pii: S0169-5002(19)30355.
    PubMed     Text format     Abstract available
    
    
31. ZHOU K, Zhou J, Huang J, Zhang N, et al
    Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
    Lung Cancer. 2019;130:1-4.
    PubMed     Text format     Abstract available
    
    
32. ZHAO S, Gao G, Li W, Li X, et al
    Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Lung Cancer. 2019;130:10-17.
    PubMed     Text format     Abstract available
    
    
33. GEERSE OP, Brandenbarg D, Kerstjens HAM, Berendsen AJ, et al
    The distress thermometer as a prognostic tool for one-year survival among patients with lung cancer.
    Lung Cancer. 2019;130:101-107.
    PubMed     Text format     Abstract available
    
    
34. MELTZER LR, Unrod M, Simmons VN, Brandon KO, et al
    Capitalizing on a teachable moment: Development of a targeted self-help smoking cessation intervention for patients receiving lung cancer screening.
    Lung Cancer. 2019;130:121-127.
    PubMed     Text format     Abstract available
    
    
35. COSTANTINI A, Fallet V, Corny J, Friard S, et al
    Nivolumab-refractory patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2019;130:128-134.
    PubMed     Text format     Abstract available
    
    
36. PERUMAL E, So Youn K, Sun S, Seung-Hyun J, et al
    PTEN inactivation induces epithelial-mesenchymal transition and metastasis by intranuclear translocation of beta-catenin and snail/slug in non-small cell lung carcinoma cells.
    Lung Cancer. 2019;130:25-34.
    PubMed     Text format     Abstract available
    
    
37. YONESHIMA Y, Tanaka K, Shiraishi Y, Hata K, et al
    Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.
    Lung Cancer. 2019;130:5-9.
    PubMed     Text format     Abstract available
    
    
38. LA FLEUR L, Falk-Sorqvist E, Smeds P, Berglund A, et al
    Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    Lung Cancer. 2019;130:50-58.
    PubMed     Text format     Abstract available
    
    
39. GUBENS MA, Sequist LV, Stevenson JP, Powell SF, et al
    Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
    Lung Cancer. 2019;130:59-66.
    PubMed     Text format     Abstract available
    
    
40. ARRIETA O, Barron F, Maldonado F, Cabrera L, et al
    Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
    Lung Cancer. 2019;130:67-75.
    PubMed     Text format     Abstract available
    
    
41. JIANG T, Bai Y, Zhou F, Li W, et al
    Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Lung Cancer. 2019;130:76-83.
    PubMed     Text format     Abstract available
    
    
42. LEE K, Kim Y, Jung HA, Lee SH, et al
    Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
    Lung Cancer. 2019;130:87-92.
    PubMed     Text format     Abstract available
    
    
43. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
    Lung Cancer. 2019;130:93-100.
    PubMed     Text format     Abstract available
    
    
44. STEFFENS CC, Elender C, Hutzschenreuter U, Dille S, et al
    Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
    Lung Cancer. 2019;130:216-225.
    PubMed     Text format     Abstract available
    
    
45. CARNEIRO-LOBO TC, Scalabrini LC, Magalhaes LDS, Cardeal LB, et al
    IKKbeta targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
    Lung Cancer. 2019;130:169-178.
    PubMed     Text format     Abstract available
    
    
46. LUO Q, Steinberg J, O'Connell DL, Yu XQ, et al
    Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?
    Lung Cancer. 2019;130:208-215.
    PubMed     Text format     Abstract available
    
    
47. BRONSERUD MM, Iachina M, Green A, Groenvold M, et al
    Patient reported outcome data as performance indicators in surgically treated lung cancer patients.
    Lung Cancer. 2019;130:143-148.
    PubMed     Text format     Abstract available
    
    
48. WU YL, Zhou C, Lu S, Qin S, et al
    Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
    Lung Cancer. 2019;130:18-24.
    PubMed     Text format     Abstract available
    
    
49. SAKATA Y, Kawamura K, Ichikado K, Shingu N, et al
    The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
    Lung Cancer. 2019;130:159-161.
    PubMed     Text format     Abstract available
    
    
50. FOSTER CC, Rusthoven CG, Sher DJ, Feldman L, et al
    Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
    Lung Cancer. 2019;130:162-168.
    PubMed     Text format     Abstract available
    
    

    
    Lung Cancer (Auckl)

51. ZHU VW, Schrock AB, Ali SM, Ou SI, et al
    Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification.
    Lung Cancer (Auckl). 2019;10:21-26.
    PubMed     Text format     Abstract available
    
    

    
    Mol Carcinog

52. YOO SM, Lee CJ, Kang HC, Lee HS, et al
    Epimagnolin targeting on an active pocket of mammalian target of rapamycin suppressed cell transformation and colony growth of lung cancer cells.
    Mol Carcinog. 2019 Mar 18. doi: 10.1002/mc.23005.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

53. WANG S, Niu X, Bao X, Wang Q, et al
    The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
    Oncol Rep. 2019 Mar 20. doi: 10.3892/or.2019.7080.
    PubMed     Text format     Abstract available
    
    
54. QIN X, Chen Z
    Metabolic dependence of cyclosporine A on cell proliferation of human nonsmall cell lung cancer A549 cells and its implication in posttransplant malignancy.
    Oncol Rep. 2019 Mar 18. doi: 10.3892/or.2019.7076.
    PubMed     Text format     Abstract available
    
    
55. LU J, Gu X, Liu F, Rui Z, et al
    Antitumor effects of hsamiR6613p on nonsmall cell lung cancer in vivo and in vitro.
    Oncol Rep. 2019 Mar 21. doi: 10.3892/or.2019.7084.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

56. DUAH E, Teegala LR, Kondeti V, Adapala RK, et al
    Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis.
    Proc Natl Acad Sci U S A. 2019;116:199-204.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: